Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges
Jean‐François Dufour, Cyrielle Caussy, Rohit Loomba
Gut (2020) Vol. 69, Iss. 10, pp. 1877-1884
Open Access | Times Cited: 168

Showing 1-25 of 168 citing articles:

Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans
Kalliopi Pafili, Michael Roden
Molecular Metabolism (2020) Vol. 50, pp. 101122-101122
Open Access | Times Cited: 235
Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials
Alessandro Mantovani, Graziana Petracca, Giorgia Beatrice, et al.
Metabolites (2021) Vol. 11, Iss. 2, pp. 73-73
Open Access | Times Cited: 214
Treatments for NAFLD: State of Art
Alessandro Mantovani, Andrea Dalbeni
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 5, pp. 2350-2350
Open Access | Times Cited: 160
Current treatment of non‐alcoholic fatty liver disease
Rafael Paternostro, Michael Trauner
Journal of Internal Medicine (2022) Vol. 292, Iss. 2, pp. 190-204
Open Access | Times Cited: 156
The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk
Cyrielle Caussy, Adrien Aubin, Rohit Loomba
Current Diabetes Reports (2021) Vol. 21, Iss. 5
Open Access | Times Cited: 146
Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial
Naim Alkhouri, Robert Herring, Heidi Kabler, et al.
Journal of Hepatology (2022) Vol. 77, Iss. 3, pp. 607-618
Open Access | Times Cited: 140
Novel therapeutic targets for cholestatic and fatty liver disease
Michael Trauner, Claudia Fuchs
Gut (2021) Vol. 71, Iss. 1, pp. 194-209
Open Access | Times Cited: 129
Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Kuei‐Chuan Lee, Pei-Shan Wu, Han‐Chieh Lin
Clinical and Molecular Hepatology (2022) Vol. 29, Iss. 1, pp. 77-98
Open Access | Times Cited: 102
Clinical Trial Landscape in NASH
Stephen A. Harrison, Rohit Loomba, Julie Dubourg, et al.
Clinical Gastroenterology and Hepatology (2023) Vol. 21, Iss. 8, pp. 2001-2014
Closed Access | Times Cited: 74
Metabolic dysfunction–associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment
Paloma Sangro, Manuel de la Torre‐Aláez, Bruno Sangro, et al.
Journal of Physiology and Biochemistry (2023) Vol. 79, Iss. 4, pp. 869-879
Open Access | Times Cited: 60
FXR agonists in NASH treatment
Luciano Adorini, Michael Trauner
Journal of Hepatology (2023) Vol. 79, Iss. 5, pp. 1317-1331
Open Access | Times Cited: 46
Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling
Elena Kotsiliti, Valentina Leone, Svenja Schuehle, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 2, pp. 296-313
Open Access | Times Cited: 44
Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
Maximilian Huttasch, Michael Roden, S. Kahl
Metabolism (2024) Vol. 157, pp. 155937-155937
Open Access | Times Cited: 29
An international multidisciplinary consensus on pediatric metabolic dysfunction-associated fatty liver disease
Le Zhang, Mortada El‐Shabrawi, Louise A. Baur, et al.
Med (2024) Vol. 5, Iss. 7, pp. 797-815.e2
Closed Access | Times Cited: 16
Metabolic Dysfunction–Associated Steatotic Liver Disease: From Pathogenesis to Current Therapeutic Options
Piero Portincasa, Mohamad Khalil, Laura Mahdi, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 11, pp. 5640-5640
Open Access | Times Cited: 16
Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease
Juan Pablo Arab, Melisa Dirchwolf, Mário Reis Álvares‐da‐Silva, et al.
Annals of Hepatology (2020) Vol. 19, Iss. 6, pp. 674-690
Open Access | Times Cited: 109
Non-Alcoholic Steatohepatitis (NASH) – A Review of a Crowded Clinical Landscape, Driven by a Complex Disease
Julia M. Fraile, Soumya Palliyil, Caroline J. Barelle, et al.
Drug Design Development and Therapy (2021) Vol. Volume 15, pp. 3997-4009
Open Access | Times Cited: 96
Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?
Agostino Di Ciaula, Salvatore Passarella, Harshitha Shanmugam, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 10, pp. 5375-5375
Open Access | Times Cited: 92
Systematic review with network meta‐analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH
Abdul M. Majzoub, Tarek Nayfeh, Abbey Barnard, et al.
Alimentary Pharmacology & Therapeutics (2021) Vol. 54, Iss. 7, pp. 880-889
Open Access | Times Cited: 67
Hepatic macrophage targeted siRNA lipid nanoparticles treat non-alcoholic steatohepatitis
Jinge Zhou, Lei Sun, Li Liu, et al.
Journal of Controlled Release (2022) Vol. 343, pp. 175-186
Closed Access | Times Cited: 64
Genome‐Wide Association Study of NAFLD Using Electronic Health Records
Cameron J. Fairfield, Thomas M Drake, Riinu Pius, et al.
Hepatology Communications (2021) Vol. 6, Iss. 2, pp. 297-308
Open Access | Times Cited: 61
PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients
Naomi F. Lange, Vanessa Graf, Cyrielle Caussy, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 8, pp. 4305-4305
Open Access | Times Cited: 54
A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis
Stephen A. Harrison, Peter Ruane, B. Freilich, et al.
JHEP Reports (2022) Vol. 5, Iss. 1, pp. 100563-100563
Open Access | Times Cited: 53
Comparative efficacy of an optimal exam between ultrasound versus abbreviated MRI for HCC screening in NAFLD cirrhosis: A prospective study
Daniel Q. Huang, Kathryn J. Fowler, Joy Liau, et al.
Alimentary Pharmacology & Therapeutics (2022) Vol. 55, Iss. 7, pp. 820-827
Open Access | Times Cited: 44
Treating inflammation to combat non-alcoholic fatty liver disease
Leke Wiering, Frank Tacke
Journal of Endocrinology (2022) Vol. 256, Iss. 1
Open Access | Times Cited: 42
Page 1 - Next Page

Scroll to top